Skip to content

Sarcopenia in COPD Patients: a French Study

Prevalence of Sarcopenia in Chronic Obstructive Patients Hospitalized in Pneumology at the CHU of Clermont-Ferrand

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03111849
Acronym
SARCOBS
Enrollment
54
Registered
2017-04-13
Start date
2017-01-31
Completion date
2017-11-30
Last updated
2018-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD, Sarcopenia, Prevalence, Mortality, Malnutrition, Nutritional assessment, Body composition, Pulmonary cachexia

Brief summary

The prevalence of sarcopenia is high in many organ pathologies such as COPD, but remains little studied in acute respiratory failure. Sarcopenia is a health problem representative of frailty, loss of autonomy and decreased muscle strength. The frequency and evolution of sarcopenia is unknown in patients having chronic bronchic obstruction with exacerbation.

Detailed description

* Investigator consecutively included patients with known persistent airflow obstruction, hospitalized in Pneumology Department at the CHU Gabriel Montpied in Clermont-Ferrand. * Investigator offered to participate to an observational study involving nutritional evaluation (recommended by national and international authorities) complementary to their usual respiratory care, and a 6 months' follow-up consultation: examination and surveys, mid-arm muscle circumference, body composition, spirometry. * This enables to assess sarcopenia as a low mid-arm muscle area, by measuring the mid-arm muscle circumference of the dominant side and the triceps skinfold thickness. * The primary endpoint is to determine the prevalence of sarcopenia, via the brachial muscular circumference, of chronic obstructive patients hospitalized in Pneumology department. * The data entry (clinical, biological and radiological) is carried out on site, during the initial consultation and follow-up, directly on the computerized patient file. These data will then be retrieved and entered in an Excel spreadsheet, anonymously (anonymous identification number, gender and age). * Management of censored data (lost to follow-up, cessation or withdrawal of study): each patient has a computerized patient record with phone numbers, checked during the first consultation and updated if necessary. The patient is called back one month before the follow-up consultation to confirm the appointment. If it is impossible to come, the patient will be offered another appointment, within one month of his initial appointment. * Lost participants will not be excluded from statistical analyses. * The expected number of subjects is 50. * Oral and written consent is asked at the beginning of the consultation proposing participation in the study and follow-up at 6 months.

Interventions

OTHERsarcopenia

Prevalence of sarcopenia in hospitalized chronic obstructive patients

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * A history of persistent airflow obstruction (a post-bronchodilator FEV1/FVC \< 0.7 of the predicted value after 400 ug of inhaled salbutamol) compatible with respiratory function tests (according to the GOLD definition) * Informed consent to examination of nutritional status

Exclusion criteria

* Bronchopulmonary cancer being treated * Disabling rheumatic disease * Recent stroke or surgery (\< 3 months) * Missing data on essential variables (BMI, mid-arm muscle circumference)

Design outcomes

Primary

MeasureTime frame
Prevalence of sarcopenia in hospitalized chronic obstructive patientsat day 1

Secondary

MeasureTime frame
Evolution of sarcopenia after hospitalizationat day 1
Determination of the factors influencing this evolutionat day 1
Determination of phenotypes from anthropometric, functional and nutritional biological parametersat day 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026